FDA Approves Arcutis Biotherapeutics’ Zoryve Foam for Seborrheic Dermatitis Treatment
Arcutis Biotherapeutics has received FDA approval for its new drug, zoryve topical foam, as a treatment for seborrheic dermatitis....
zoryve topical foam
Stocks to Watch: Arcutis Biotherapeutics, Minerva Surgical, Enzo Biochem
Arcutis Biotherapeutics has received FDA approval for its Zoryve topical foam, a treatment for seborrheic dermatitis. The company plans...
Arcutis Biotherapeutics Shares Surge on FDA Approval for Skin-Condition Treatment
Arcutis Biotherapeutics' stock surged 18% in after-hours trading after the FDA approved their treatment for seborrheic dermatitis, a skin...